Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
4.950
-0.200 (-3.88%)
Mar 31, 2025, 3:13 PM EDT - Market open
Cara Therapeutics Revenue
In the year 2024, Cara Therapeutics had annual revenue of $7.14M, down -65.96%. Cara Therapeutics had revenue of $1.46M in the quarter ending December 31, 2024, a decrease of -51.56%.
Revenue (ttm)
$7.14M
Revenue Growth
-65.96%
P/S Ratio
3.29
Revenue / Employee
$713,700
Employees
10
Market Cap
22.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.14M | -13.83M | -65.96% |
Dec 31, 2023 | 20.97M | -20.90M | -49.92% |
Dec 31, 2022 | 41.87M | 18.84M | 81.81% |
Dec 31, 2021 | 23.03M | -112.05M | -82.95% |
Dec 31, 2020 | 135.08M | 115.20M | 579.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CARA News
- 5 weeks ago - CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA - Business Wire
- 3 months ago - Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - GlobeNewsWire
- 3 months ago - Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement - GlobeNewsWire
- 10 months ago - These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - Benzinga
- 10 months ago - Cara Therapeutics discontinues study on a neurological condition as drug fails - Reuters
- 10 months ago - Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica - GlobeNewsWire
- 11 months ago - Cara Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 11 months ago - Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 - GlobeNewsWire